An RCT to Evaluate Incidence, Cost and Clinical Outcomes Using 75 vs 100g. Screening Methods for Gestational Diabetes

This study has been completed.
Sponsor:
Information provided by:
Canadian Diabetes Association
ClinicalTrials.gov Identifier:
NCT00295659
First received: February 22, 2006
Last updated: October 17, 2006
Last verified: September 2005
  Purpose

Diabetes in pregnancy or gestational diabetes (GDM) is a condition that, if left untreated, may lead to complications for the mother and her baby. It is still not known which is the best method to diagnosis GDM. The goal of this study is to compare three well-accepted methods for diagnosis of GDM (using either 75 g or 100 g in the glucose tolerance test) and determine which method is the easiest and least expensive to use in relation to the reference method used over the last 20 years. The goal is to see if they can equally predict the healthy outcome of the pregnant mother and her newborn.


Condition
Gestational Diabetes

Study Type: Observational
Study Design: Allocation: Random Sample
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Official Title: What is the Optimal Method for Screening and Diagnosis of Gestational Diabetes? An RCT to Evaluate Incidence, Cost-Effectiveness and Clinical Outcomes Using Three Methods

Resource links provided by NLM:


Further study details as provided by Canadian Diabetes Association:

Estimated Enrollment: 5800
Study Start Date: January 2001
Estimated Study Completion Date: September 2004
Detailed Description:

Title: What is the optimal method for screening and diagnosis of gestational diabetes? A randomised clinical trial to evaluate incidence of GDM, cost-effectiveness and clinical outcomes using three methods.

Objectives: 1) To evaluate the incidence and cost-effectiveness of screening and diagnosis of GDM by comparing three different methods. 2) To evaluate the following by each method: population characteristics; gestational age at screening, diagnosis and initiation of treatment; and maternal and neonatal outcomes.

Rationale: There is no consensus on the best method to identify cases of GDM, numerous screening and diagnostic procedures are employed worldwide. Recently the Canadian Guidelines recommended a new set of values based on normative data, yet these data have not been validated against a large population and compared with diagnostic rates and outcomes head to head against the long accepted values of O’Sullivan and Mahan. In addition, the question of cost in a Canadian healthcare setting has never been addressed yet it is a significant societal concern. The results of this study would help clarify these issues using evidence-based methodology.

Outline: Pregnant women referred as outpatients for glucose testing for GDM will be given a study information sheet by obstetrics staff. At the time of booking the test they will be reminded of the study and to arrive fasting. On the day of glucose testing, the research assistant will invite patients to participate, obtain consent and perform randomisation into one three groups:

(1) 50g screen ± 100g 3h GTT; (2) 50g screen ± 75g 2h GTT; or (3) 75g 2h GTT. During the glucose test, study participants will also be asked information on health and costs incurred for the process of glucose testing. If the screen or GTT needs to be repeated at some time during the pregnancy, patients will remain in the same study arm as originally assigned. Interpretation of results by patient’s caregivers and referral to the diabetes clinic as needed will continue as usual. Data will be analysed using appropriate bivariate and multivariate methods for GDM incidence, direct and indirect costs of glucose testing, and maternal and infant outcomes.

Significance to DM: This study will evaluate the diagnostic efficacy, cost-effectiveness and clinical outcomes of three methods. A one-step procedure may be better tolerated compared to a two-step approach with respect to number of visits, amount of drink and length of testing. Furthermore, diagnosis by a single test may avoid unnecessary delay in initiation of therapy and still identify those patients at risk for type 2 DM.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • all women presenting for glucose screening in pregnancy between January 2001 and June, 2004 at a tertiary care university hospital setting

Exclusion Criteria:

  • insufficient knowledge of French or English; known diabetes; refusal to participate; error in protocol; not fasting when presenting for study test
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00295659

Locations
Canada, Quebec
Royal Victoria Hospital, McGill University Health Centre
Montreal, Quebec, Canada, H3A 1A1
Sponsors and Collaborators
Canadian Diabetes Association
Investigators
Principal Investigator: Sara J Meltzer, MD, FRCPC McGill Unversity, Faculty of Medicine, Dept. of Medicine and Obstetrics and Gynecology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00295659     History of Changes
Other Study ID Numbers: CDA 200665
Study First Received: February 22, 2006
Last Updated: October 17, 2006
Health Authority: Canada: Ethics Review Committee

Keywords provided by Canadian Diabetes Association:
Gestational Diabetes
Screening
Cost-effectiveness
obstetrical outcomes

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Pregnancy Complications

ClinicalTrials.gov processed this record on October 29, 2014